Addition of fexofenadine to inhaled corticosteroid therapy to reduce inflammatory biomarkers in atopic asthma
We previously showed that H 1-antihistamines may shift the PC 20 (provocation concentration that caused a decrease in forced expiratory volume in 1 second of 20%) threshold to adenosine monophosphate (AMP) challenge but may paradoxically prolong recovery. To measure AMP recovery using a constant pre...
Gespeichert in:
| Veröffentlicht in: | Annals of allergy, asthma, & immunology asthma, & immunology, 2005-09, Vol.95 (3), p.259-265 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 265 |
|---|---|
| container_issue | 3 |
| container_start_page | 259 |
| container_title | Annals of allergy, asthma, & immunology |
| container_volume | 95 |
| creator | Fardon, Tom C. Lee, Daniel K.C. Hodge, Melissa R. Lipworth, Brian J. |
| description | We previously showed that H
1-antihistamines may shift the PC
20 (provocation concentration that caused a decrease in forced expiratory volume in 1 second of 20%) threshold to adenosine monophosphate (AMP) challenge but may paradoxically prolong recovery.
To measure AMP recovery using a constant predetermined AMP PC
20 and to evaluate whether fexofenadine use confers add-on effects to treatment with either fluticasone propionate alone or combined fluticasone propionate-salmeterol.
Fourteen atopic patients with mild-to-moderate asthma (forced expiratory volume in 1 second of 76%) completed a double-blind, randomized, crossover study consisting of 3-week treatment blocks of either fluticasone propionate-salmeterol, 250 μg twice daily, or fluticasone propionate alone, 250 μg twice daily, in conjunction with either fexofenadine, 180 mg once daily, or matched placebo. Recovery after a predetermined AMP PC
20 challenge was measured (primary outcome), along with exhaled nitric oxide levels, plasma eosinophil cationic protein levels, peripheral eosinophil counts, pulmonary function, diary card outcomes, and quality of life (all secondary outcomes).
There were no differences in any of the primary or secondary outcomes when fexofenadine was added to treatment with either fluticasone propionate-salmeterol or fluticasone propionate alone. The mean AMP recovery time was 25.0 vs 23.4 minutes for fexofenadine and placebo, respectively, as add-on to fluticasone-salmeterol and 22.5 vs 23.9 minutes, respectively, as add-on to fluticasone alone.
Fexofenadine did not affect recovery to a fixed dose of AMP challenge or any other surrogate inflammatory markers when given as add-on therapy to corticosteroid-treated atopic asthmatic patients. |
| doi_str_mv | 10.1016/S1081-1206(10)61223-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68653823</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1081120610612239</els_id><sourcerecordid>903477841</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-4526143ea2f33f5a97e2c2c2c945c1e3c092f3344c93a1f7f62620839b0a7aab3</originalsourceid><addsrcrecordid>eNqFkV1rFTEQhoNYbK3-BCUIil6s5muzu1dSih-FghfqdZiTTDipu5tjkpWef99sz5GCN5KLCTPPDDPvS8gLzt5zxvWH75z1vOGC6becvdNcCNkMj8gZb6VqlJL6cf3_RU7J05xvGGO81_IJOeVasFrrzsh04VwoIc40eurxNnqcwYUZaYk0zFsY0VEbUwk25oIpBkfLFhPs9iuR0C0WK-hHmCYoMe3pJsQJ0i9MueZpze2CpZDLdoJn5MTDmPH5MZ6Tn58__bj82lx_-3J1eXHdWCVYaVQrNFcSQXgpfQtDh8Kub1Ct5SgtG9aKUnaQwH3ntagH9XLYMOgANvKcvDnM3aX4e8FczBSyxXGEGeOSje51K3shK_jqH_AmLmmuuxnBRNcrKfoKtQfIpphzQm92KdQT94Yzs5ph7s0wq9Jr6t4MM9S-l8fhy2ZC99B1VL8Cr48AZAujTzDbkB-4jvOBtesCHw8cVs3-BEwm24CzRRcS2mJcDP9Z5Q5qbaaV</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>202784328</pqid></control><display><type>article</type><title>Addition of fexofenadine to inhaled corticosteroid therapy to reduce inflammatory biomarkers in atopic asthma</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Fardon, Tom C. ; Lee, Daniel K.C. ; Hodge, Melissa R. ; Lipworth, Brian J.</creator><creatorcontrib>Fardon, Tom C. ; Lee, Daniel K.C. ; Hodge, Melissa R. ; Lipworth, Brian J.</creatorcontrib><description>We previously showed that H
1-antihistamines may shift the PC
20 (provocation concentration that caused a decrease in forced expiratory volume in 1 second of 20%) threshold to adenosine monophosphate (AMP) challenge but may paradoxically prolong recovery.
To measure AMP recovery using a constant predetermined AMP PC
20 and to evaluate whether fexofenadine use confers add-on effects to treatment with either fluticasone propionate alone or combined fluticasone propionate-salmeterol.
Fourteen atopic patients with mild-to-moderate asthma (forced expiratory volume in 1 second of 76%) completed a double-blind, randomized, crossover study consisting of 3-week treatment blocks of either fluticasone propionate-salmeterol, 250 μg twice daily, or fluticasone propionate alone, 250 μg twice daily, in conjunction with either fexofenadine, 180 mg once daily, or matched placebo. Recovery after a predetermined AMP PC
20 challenge was measured (primary outcome), along with exhaled nitric oxide levels, plasma eosinophil cationic protein levels, peripheral eosinophil counts, pulmonary function, diary card outcomes, and quality of life (all secondary outcomes).
There were no differences in any of the primary or secondary outcomes when fexofenadine was added to treatment with either fluticasone propionate-salmeterol or fluticasone propionate alone. The mean AMP recovery time was 25.0 vs 23.4 minutes for fexofenadine and placebo, respectively, as add-on to fluticasone-salmeterol and 22.5 vs 23.9 minutes, respectively, as add-on to fluticasone alone.
Fexofenadine did not affect recovery to a fixed dose of AMP challenge or any other surrogate inflammatory markers when given as add-on therapy to corticosteroid-treated atopic asthmatic patients.</description><identifier>ISSN: 1081-1206</identifier><identifier>EISSN: 1534-4436</identifier><identifier>DOI: 10.1016/S1081-1206(10)61223-9</identifier><identifier>PMID: 16200817</identifier><identifier>CODEN: ANAEA3</identifier><language>eng</language><publisher>McLean, VA: Elsevier Inc</publisher><subject>Adenosine Monophosphate - immunology ; Administration, Inhalation ; Adolescent ; Adrenal Cortex Hormones - administration & dosage ; Adult ; Albuterol - analogs & derivatives ; Albuterol - therapeutic use ; Androstadienes - therapeutic use ; Anti-Allergic Agents - therapeutic use ; Asthma - drug therapy ; Biological and medical sciences ; Biomarkers ; Bronchial Provocation Tests ; Chronic obstructive pulmonary disease, asthma ; Drug Therapy, Combination ; Eosinophil Cationic Protein - blood ; Eosinophil Cationic Protein - drug effects ; Eosinophils - drug effects ; Female ; Fluticasone ; Humans ; Hypersensitivity, Immediate - drug therapy ; Immunopathology ; Inflammation - immunology ; Male ; Medical sciences ; Nitric Oxide - analysis ; Pneumology ; Respiratory Function Tests ; Salmeterol Xinafoate ; Terfenadine - analogs & derivatives ; Terfenadine - therapeutic use ; Treatment Outcome</subject><ispartof>Annals of allergy, asthma, & immunology, 2005-09, Vol.95 (3), p.259-265</ispartof><rights>2005 American College of Allergy, Asthma & Immunology</rights><rights>2005 INIST-CNRS</rights><rights>Copyright American College of Allergy and Immunology Sep 2005</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-4526143ea2f33f5a97e2c2c2c945c1e3c092f3344c93a1f7f62620839b0a7aab3</citedby><cites>FETCH-LOGICAL-c420t-4526143ea2f33f5a97e2c2c2c945c1e3c092f3344c93a1f7f62620839b0a7aab3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S1081-1206(10)61223-9$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17119058$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16200817$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fardon, Tom C.</creatorcontrib><creatorcontrib>Lee, Daniel K.C.</creatorcontrib><creatorcontrib>Hodge, Melissa R.</creatorcontrib><creatorcontrib>Lipworth, Brian J.</creatorcontrib><title>Addition of fexofenadine to inhaled corticosteroid therapy to reduce inflammatory biomarkers in atopic asthma</title><title>Annals of allergy, asthma, & immunology</title><addtitle>Ann Allergy Asthma Immunol</addtitle><description>We previously showed that H
1-antihistamines may shift the PC
20 (provocation concentration that caused a decrease in forced expiratory volume in 1 second of 20%) threshold to adenosine monophosphate (AMP) challenge but may paradoxically prolong recovery.
To measure AMP recovery using a constant predetermined AMP PC
20 and to evaluate whether fexofenadine use confers add-on effects to treatment with either fluticasone propionate alone or combined fluticasone propionate-salmeterol.
Fourteen atopic patients with mild-to-moderate asthma (forced expiratory volume in 1 second of 76%) completed a double-blind, randomized, crossover study consisting of 3-week treatment blocks of either fluticasone propionate-salmeterol, 250 μg twice daily, or fluticasone propionate alone, 250 μg twice daily, in conjunction with either fexofenadine, 180 mg once daily, or matched placebo. Recovery after a predetermined AMP PC
20 challenge was measured (primary outcome), along with exhaled nitric oxide levels, plasma eosinophil cationic protein levels, peripheral eosinophil counts, pulmonary function, diary card outcomes, and quality of life (all secondary outcomes).
There were no differences in any of the primary or secondary outcomes when fexofenadine was added to treatment with either fluticasone propionate-salmeterol or fluticasone propionate alone. The mean AMP recovery time was 25.0 vs 23.4 minutes for fexofenadine and placebo, respectively, as add-on to fluticasone-salmeterol and 22.5 vs 23.9 minutes, respectively, as add-on to fluticasone alone.
Fexofenadine did not affect recovery to a fixed dose of AMP challenge or any other surrogate inflammatory markers when given as add-on therapy to corticosteroid-treated atopic asthmatic patients.</description><subject>Adenosine Monophosphate - immunology</subject><subject>Administration, Inhalation</subject><subject>Adolescent</subject><subject>Adrenal Cortex Hormones - administration & dosage</subject><subject>Adult</subject><subject>Albuterol - analogs & derivatives</subject><subject>Albuterol - therapeutic use</subject><subject>Androstadienes - therapeutic use</subject><subject>Anti-Allergic Agents - therapeutic use</subject><subject>Asthma - drug therapy</subject><subject>Biological and medical sciences</subject><subject>Biomarkers</subject><subject>Bronchial Provocation Tests</subject><subject>Chronic obstructive pulmonary disease, asthma</subject><subject>Drug Therapy, Combination</subject><subject>Eosinophil Cationic Protein - blood</subject><subject>Eosinophil Cationic Protein - drug effects</subject><subject>Eosinophils - drug effects</subject><subject>Female</subject><subject>Fluticasone</subject><subject>Humans</subject><subject>Hypersensitivity, Immediate - drug therapy</subject><subject>Immunopathology</subject><subject>Inflammation - immunology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Nitric Oxide - analysis</subject><subject>Pneumology</subject><subject>Respiratory Function Tests</subject><subject>Salmeterol Xinafoate</subject><subject>Terfenadine - analogs & derivatives</subject><subject>Terfenadine - therapeutic use</subject><subject>Treatment Outcome</subject><issn>1081-1206</issn><issn>1534-4436</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkV1rFTEQhoNYbK3-BCUIil6s5muzu1dSih-FghfqdZiTTDipu5tjkpWef99sz5GCN5KLCTPPDDPvS8gLzt5zxvWH75z1vOGC6becvdNcCNkMj8gZb6VqlJL6cf3_RU7J05xvGGO81_IJOeVasFrrzsh04VwoIc40eurxNnqcwYUZaYk0zFsY0VEbUwk25oIpBkfLFhPs9iuR0C0WK-hHmCYoMe3pJsQJ0i9MueZpze2CpZDLdoJn5MTDmPH5MZ6Tn58__bj82lx_-3J1eXHdWCVYaVQrNFcSQXgpfQtDh8Kub1Ct5SgtG9aKUnaQwH3ntagH9XLYMOgANvKcvDnM3aX4e8FczBSyxXGEGeOSje51K3shK_jqH_AmLmmuuxnBRNcrKfoKtQfIpphzQm92KdQT94Yzs5ph7s0wq9Jr6t4MM9S-l8fhy2ZC99B1VL8Cr48AZAujTzDbkB-4jvOBtesCHw8cVs3-BEwm24CzRRcS2mJcDP9Z5Q5qbaaV</recordid><startdate>20050901</startdate><enddate>20050901</enddate><creator>Fardon, Tom C.</creator><creator>Lee, Daniel K.C.</creator><creator>Hodge, Melissa R.</creator><creator>Lipworth, Brian J.</creator><general>Elsevier Inc</general><general>American College of Allergy, Asthma, & Immunology</general><general>American College of Allergy and Immunology</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20050901</creationdate><title>Addition of fexofenadine to inhaled corticosteroid therapy to reduce inflammatory biomarkers in atopic asthma</title><author>Fardon, Tom C. ; Lee, Daniel K.C. ; Hodge, Melissa R. ; Lipworth, Brian J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-4526143ea2f33f5a97e2c2c2c945c1e3c092f3344c93a1f7f62620839b0a7aab3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adenosine Monophosphate - immunology</topic><topic>Administration, Inhalation</topic><topic>Adolescent</topic><topic>Adrenal Cortex Hormones - administration & dosage</topic><topic>Adult</topic><topic>Albuterol - analogs & derivatives</topic><topic>Albuterol - therapeutic use</topic><topic>Androstadienes - therapeutic use</topic><topic>Anti-Allergic Agents - therapeutic use</topic><topic>Asthma - drug therapy</topic><topic>Biological and medical sciences</topic><topic>Biomarkers</topic><topic>Bronchial Provocation Tests</topic><topic>Chronic obstructive pulmonary disease, asthma</topic><topic>Drug Therapy, Combination</topic><topic>Eosinophil Cationic Protein - blood</topic><topic>Eosinophil Cationic Protein - drug effects</topic><topic>Eosinophils - drug effects</topic><topic>Female</topic><topic>Fluticasone</topic><topic>Humans</topic><topic>Hypersensitivity, Immediate - drug therapy</topic><topic>Immunopathology</topic><topic>Inflammation - immunology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Nitric Oxide - analysis</topic><topic>Pneumology</topic><topic>Respiratory Function Tests</topic><topic>Salmeterol Xinafoate</topic><topic>Terfenadine - analogs & derivatives</topic><topic>Terfenadine - therapeutic use</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fardon, Tom C.</creatorcontrib><creatorcontrib>Lee, Daniel K.C.</creatorcontrib><creatorcontrib>Hodge, Melissa R.</creatorcontrib><creatorcontrib>Lipworth, Brian J.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of allergy, asthma, & immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fardon, Tom C.</au><au>Lee, Daniel K.C.</au><au>Hodge, Melissa R.</au><au>Lipworth, Brian J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Addition of fexofenadine to inhaled corticosteroid therapy to reduce inflammatory biomarkers in atopic asthma</atitle><jtitle>Annals of allergy, asthma, & immunology</jtitle><addtitle>Ann Allergy Asthma Immunol</addtitle><date>2005-09-01</date><risdate>2005</risdate><volume>95</volume><issue>3</issue><spage>259</spage><epage>265</epage><pages>259-265</pages><issn>1081-1206</issn><eissn>1534-4436</eissn><coden>ANAEA3</coden><abstract>We previously showed that H
1-antihistamines may shift the PC
20 (provocation concentration that caused a decrease in forced expiratory volume in 1 second of 20%) threshold to adenosine monophosphate (AMP) challenge but may paradoxically prolong recovery.
To measure AMP recovery using a constant predetermined AMP PC
20 and to evaluate whether fexofenadine use confers add-on effects to treatment with either fluticasone propionate alone or combined fluticasone propionate-salmeterol.
Fourteen atopic patients with mild-to-moderate asthma (forced expiratory volume in 1 second of 76%) completed a double-blind, randomized, crossover study consisting of 3-week treatment blocks of either fluticasone propionate-salmeterol, 250 μg twice daily, or fluticasone propionate alone, 250 μg twice daily, in conjunction with either fexofenadine, 180 mg once daily, or matched placebo. Recovery after a predetermined AMP PC
20 challenge was measured (primary outcome), along with exhaled nitric oxide levels, plasma eosinophil cationic protein levels, peripheral eosinophil counts, pulmonary function, diary card outcomes, and quality of life (all secondary outcomes).
There were no differences in any of the primary or secondary outcomes when fexofenadine was added to treatment with either fluticasone propionate-salmeterol or fluticasone propionate alone. The mean AMP recovery time was 25.0 vs 23.4 minutes for fexofenadine and placebo, respectively, as add-on to fluticasone-salmeterol and 22.5 vs 23.9 minutes, respectively, as add-on to fluticasone alone.
Fexofenadine did not affect recovery to a fixed dose of AMP challenge or any other surrogate inflammatory markers when given as add-on therapy to corticosteroid-treated atopic asthmatic patients.</abstract><cop>McLean, VA</cop><pub>Elsevier Inc</pub><pmid>16200817</pmid><doi>10.1016/S1081-1206(10)61223-9</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1081-1206 |
| ispartof | Annals of allergy, asthma, & immunology, 2005-09, Vol.95 (3), p.259-265 |
| issn | 1081-1206 1534-4436 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68653823 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Adenosine Monophosphate - immunology Administration, Inhalation Adolescent Adrenal Cortex Hormones - administration & dosage Adult Albuterol - analogs & derivatives Albuterol - therapeutic use Androstadienes - therapeutic use Anti-Allergic Agents - therapeutic use Asthma - drug therapy Biological and medical sciences Biomarkers Bronchial Provocation Tests Chronic obstructive pulmonary disease, asthma Drug Therapy, Combination Eosinophil Cationic Protein - blood Eosinophil Cationic Protein - drug effects Eosinophils - drug effects Female Fluticasone Humans Hypersensitivity, Immediate - drug therapy Immunopathology Inflammation - immunology Male Medical sciences Nitric Oxide - analysis Pneumology Respiratory Function Tests Salmeterol Xinafoate Terfenadine - analogs & derivatives Terfenadine - therapeutic use Treatment Outcome |
| title | Addition of fexofenadine to inhaled corticosteroid therapy to reduce inflammatory biomarkers in atopic asthma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T15%3A44%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Addition%20of%20fexofenadine%20to%20inhaled%20corticosteroid%20therapy%20to%20reduce%20inflammatory%20biomarkers%20in%20atopic%20asthma&rft.jtitle=Annals%20of%20allergy,%20asthma,%20&%20immunology&rft.au=Fardon,%20Tom%20C.&rft.date=2005-09-01&rft.volume=95&rft.issue=3&rft.spage=259&rft.epage=265&rft.pages=259-265&rft.issn=1081-1206&rft.eissn=1534-4436&rft.coden=ANAEA3&rft_id=info:doi/10.1016/S1081-1206(10)61223-9&rft_dat=%3Cproquest_cross%3E903477841%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=202784328&rft_id=info:pmid/16200817&rft_els_id=S1081120610612239&rfr_iscdi=true |